Designing non-clinical safety evaluation programmes for monoclonal antibodies: Recommendations and the way forward

Author(s):  
James Green ◽  
John Purves
2007 ◽  
pp. 75-84
Author(s):  
Patricia M. Reed ◽  
Stuart J. Mair ◽  
Stephen Freestone

1992 ◽  
Vol 20 (3-2) ◽  
pp. 501-505 ◽  
Author(s):  
Dai T. Davies

This short paper will briefly discuss the merits of determining plasma enzyme activities in pre-clinical safety evaluation. Emphasis is placed on the value of selecting the appropriate enzymes and collecting blood samples at the appropriate times during the study, so as to gain the maximum amount of diagnostic information. Examples of actual results will be cited to illustrate some of the points. These examples are drawn from the 2 commonly used toxicology species—the laboratory white rat and the beagle—and serve to demonstrate the importance of enzymology in monitoring the progress or resolution of an adverse drug effect.


2016 ◽  
Vol 14 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Mohd A. Alam ◽  
Farhan J. Ahmad ◽  
Zeenat I. Khan ◽  
Roop K. Khar

2017 ◽  
Vol 65 (6) ◽  
pp. 321-333 ◽  
Author(s):  
Sari Latvala ◽  
Bjoern Jacobsen ◽  
Michael B. Otteneder ◽  
Annika Herrmann ◽  
Sven Kronenberg

The neonatal Fc receptor (FcRn) is a major histocompatibility complex class I type molecule that binds to, transports, and recycles immunoglobulin G (IgG) and albumin, thereby protecting them from lysosomal degradation. Therefore, besides the knowledge of FcRn affinity, FcRn protein expression is critical in understanding the pharmacokinetic behavior of Fc-containing biotherapeutics such as monoclonal antibodies. The goal of this investigation was to achieve for the first time a comparative assessment of FcRn distribution across a variety of tissues and species. FcRn was mapped in about 20 tissues including placenta from human and the most frequently used species in non-clinical safety testing of monoclonal antibodies (mouse, rat, cynomolgus monkey). In addition, the FcRn expression pattern was characterized in two humanized transgenic mouse lines (Tg32 and Tg276) expressing human FcRn under different promoters, and in the severe combined immunodeficient (SCID) mouse. Consecutive sections were stained with specific markers, namely, anti-CD68 for macrophages and anti–von Willebrand Factor for endothelial cells. Overall, the FcRn expression pattern was comparable across species and tissues with consistent expression of FcRn in endothelial cells and interstitial macrophages, Kupffer cells, alveolar macrophages, enterocytes, and choroid plexus epithelium. The human FcRn transgenic mouse Tg276 showed a different and much more widespread staining pattern of FcRn. In addition, immunodeficiency and lack of IgG in SCID mice had no negative effect on FcRn expression compared with wild-type mice.


Sign in / Sign up

Export Citation Format

Share Document